These therapies aim to enhance WL and improve metabolic outcomes by engaging multiple hormonal pathways, with preclinical and early-phase clinical trials supporting their potential as next-generation obesity treatments [16,17,18,19,20,21,22,23]
GLP-1 agonists were initially approved for treating type 2 diabetes, with subsequent approvals for chronic weight management and reduction of the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 diabetes
GLP-1 agonists affect the way your body signals hunger and digests food
Data and code availability statement NIH All of Us Research Program data is available to individuals at institutions who have a Data Use and Registration Agreement in place and who complete the necessary introductory, regulatory, and access protocols, which are introduced at: The code used to perform analyses conducted in this manuscript is available via GitHub: REFERENCES 1.Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J
Official Score Breakdown: PlushCare Clinical: 4.8 Support: 4.9 Patient Protection: 4.1 Cost & Value: 4.8 Access: 5.0 Trust & Transparency: 4.5 Authenticity: 5.0 Reputation: 3.2 Official Score Breakdown: Mochi Health Clinical: 4.8 Support: 4.9 Patient Protection: 4.1 Cost & Value: 4.8 Access: 4.7 Trust & Transparency: 5.0 Authenticity: 5.0 Reputation: 4.5 PlushCare: The Primary Care Approach PlushCares clinical quality score of 4.8 reflects a broad medical model rather than a narrow weight-loss funnel
Comprehensive Medical Evaluation Your doctor reviews your: Weight loss history and goals BMI and waist circumference Current medical conditions (diabetes, hypertension, heart disease, PCOS, etc.) Medications and allergies Lifestyle factors influencing your weight This is similar to the in-depth approach used in our virtual weight loss and telehealth obesity care programs
